Interleukin-33 (IL-33) has emerged as a critical cytokine in the regulation of the immune
system, showing a pivotal role in the pathogenesis of various diseases including cancer …

Cancer is initiated by mutations in critical regulatory genes; however, its progression to
malignancy is aided by non-neoplastic cells and molecules that create a permissive …

Simple Summary Interleukin-33 (IL-33) is often released from damaged cells, acting as a
danger signal. IL-33 exerts its function by interacting with its receptor suppression of …

Abstract Interleukin-33 (IL-33) is a member of the IL-1 gene family and mainly expressed in
the nucleus of tissue lining cells, stromal cells, and activated myeloid cells. IL-33 is …

Interleukin-33 (IL-33) is a recently identified cytokine, an important member of the interleukin-
1 family. IL-33 binds to its receptor ST2 to induce type 2 cytokines and exert both pro …

Abstract Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines that is constitutively
expressed in the nucleus of epithelial, endothelial and fibroblast-like cells. Upon cell stress …

Interleukin-33 (IL-33) is an epithelial-derived cytokine that can be released upon tissue
damage, stress, or infection, acting as an alarmin for the immune system. IL-33 has long …

Lung carcinogenesis is a multistep process involving genetic mutations and epigenetic
changes, with the acquisition of a malignant phenotype characterized by apoptosis …

Interleukin-33 (IL-33), considered as an alarmin released upon tissue stress or damage, is a
member of the IL-1 family and binds the ST2 receptor. First described as a potent initiator of …

Interleukin-33 (IL-33), a member of the interleukin-1 (IL-1) family of cytokines, remains poorly
understood in the context of human breast cancer and its impact on treatment outcomes …